Press Releases.

Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia

VolitionRx Limited Announces Third Quarter 2021 Financial Results and Business Update

VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update

Volition Veterinary Presents Two Posters at the 2021 Veterinary Cancer Society Conference

VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update

VolitionRx Limited Schedules Second Quarter 2021 Earnings Conference Call and Business Update

Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring

VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update

VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update

VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper

VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary

VolitionRx Limited Appoints Two New Directors

VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update

New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis

VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update

VolitionRx Limited to Present at Conferences in March 2021

VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock

VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts

National Taiwan University Hospital Presents Data on Nu.Q™ Assay Performance at the World Conference on Lung Cancer

VolitionRx Limited Opens its New Manufacturing Facility in Belgium

VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive Funding

VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors

Volition Launches Nu.Q™ Vet Cancer Screening Test in the U.S.

VolitionRx Limited to Present COVID-19 Data at MEDICA 2020

VolitionRx Limited Announces Third Quarter 2020 Financial Results and Business Update

Volition Veterinary Presents Expert Report Ahead of First Product Launch

VolitionRx Limited Schedules Third Quarter 2020 Earnings Conference Call and Business Update

VolitionRx Limited Releases Video of Virtual Capital Markets Day 2020

Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q™ Vet Cancer Screening Test in Lymphoma and Hemangiosarcoma to be Presented at the 2020 VCS Virtual Annual Conference

VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020

Volition Veterinary Diagnostics Development LLC to Present Product Data Regarding its Nu.Q™ Vet Cancer Screening Test at the 2020 VCS Virtual Annual Conference

VolitionRx Limited Announces Virtual Capital Markets Day 2020

VolitionRx Limited to Present at Conferences in September 2020

VolitionRx Limited Announces Second Quarter 2020 Financial Results and Business Update

VolitionRx Limited Schedules Second Quarter 2020 Earnings Conference Call and Business Update

Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test

VolitionRx Releases Business Update Video and Announces Addition to the Russell 3000® and Russell Microcap® Indexes

Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference

VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock

VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock

VolitionRx To Present First Data on Nu.Q™ Capture Performance and Nu.Q™ Assay Performance in Lung Cancer and Blood Cancer at the 2020 ASCO Annual Meeting

VolitionRx Limited Announces First Quarter 2020 Financial Results and Business Update

VolitionRx Limited Schedules First Quarter 2020 Earnings Conference Call and Business Update

Volition's Nu.Q™ Vet Assay Detects Two Common Canine Cancers

Volition Files Patent for Nu.Q™ COVID-19 Triage Test and Commences Proof of Concept Studies

VolitionRx Limited Releases Annual Corporate Brochure and Video

VolitionRx Limited to Present at Conferences in March 2020

VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update

VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update

Volition Unveils Its Epigenetic Toolbox

VolitionRx Announces Filing of Registration Statements

Volition Develops a New Improved Nu.Q™ Assay Format

VolitionRx Completes Acquisition of Octamer GmbH

VolitionRx Limited Announces Strategic Acquisition

VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test

VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia

VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update

VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update

Volition announces $500,000 in Non-Dilutive Funding for Volition Veterinary and issues Video

Texas A&M University Takes A 12.5% Equity Stake in Volition Veterinary Diagnostics Development LLC

Nu.Q™ Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas

Volition Appoints Dr. Phillip Barnes to Board of Directors

Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes

VolitionRx Limited Announces Second Quarter 2019 Financial Results and Business Update

Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer

VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update

Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock

VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China

VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update

VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer

VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update

VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report

VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.Q™ Veterinary Diagnostics

VolitionRx Limited Extends Clinical Trial Program in Lung Cancer

VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China

VolitionRx Limited to Present at Conferences in March & April 2019

VolitionRx Limited to Present at Conferences in the U.S. Next Week

VolitionRx Limited Announces Full Fiscal Year 2018 Financial Results and Business Update

VolitionRx Limited Schedules Full Year 2018 Earnings Conference Call and Business Update

VolitionRx Limited Announces Third Quarter 2018 Financial Results and Business Update

VolitionRx Limited Schedules Third Quarter 2018 Earnings Conference Call and Business Update

VolitionRx Limited to Expand its Nu.Q™ Trials to Veterinary Diagnostics

VolitionRx Limited Releases Video Featuring Interviews with its Scientific Advisory Board

VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update

Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer

VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study

VolitionRx Announces $9 Million Private Placement

VolitionRx Limited Schedules Second Quarter 2018 Earnings Conference Call and Business Update

VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today

Volition Extends Global Reach of its Clinical Trial Program

Volition Secures Additional $700,000 Non-Dilutive Funding from the Walloon Region

VolitionRx Limited to Attend the Bank of America Merrill Lynch 2018 Health Care Conference from May 15-17, 2018

VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update

VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits

VolitionRx Limited Schedules First Quarter 2018 Earnings Conference Call and Business Update

VolitionRx Announces Closing of $8.4 Million Public Offering of Common Stock

VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock

VolitionRx Announces Proposed Underwritten Public Offering of Common Stock

VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board

VolitionRX Limited Announces Full Fiscal Year 2017 Financial Results and Business Update

VolitionRx Limited Schedules Full Year 2017 Earnings Conference Call and Business Update

VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer

VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.

VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone

VolitionRx Limited to Attend Conferences in December

Singapore Volition signs Memorandum of Understanding with the National Taiwan University to Conduct Two Large Clinical Studies

VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update

VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update

VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits

VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding

VolitionRx Announces its European Colorectal Cancer Strategy

VolitionRx to Attend Two Major Conferences in Asia

Volition Granted Four Additional Patents

VolitionRx Limited to Attend Multiple Conferences in September

Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers

VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update

VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update

VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute

Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute

Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress

VolitionRx Limited Corrects an Earlier Announcement

VolitionRx Limited to Present at Multiple Investor Conferences in June

A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q™ assays

VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update

VolitionRx Limited Announces Final Results from 8000 Patient Clinical Trial in Denmark to Evaluate the Performance of its Nu.Q(TM) Triage Test

VolitionRx Limited Schedules First Quarter 2017 Earnings Conference Call and Business Update

Volition makes progress with its Colorectal Cancer Screening Triage Test in both Asia and Europe

Volition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory

VolitionRx Appoints David Vanston as Chief Financial Officer

Volition America, Inc. Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States

VolitionRx Limited Announces the Formation of Volition America, Inc.

VolitionRx Limited Celebrates CE Mark Announcement By Ringing Closing Bell at the New York Stock Exchange

VolitionRx Limited to Ring the New York Stock Exchange Closing Bell on Monday, March 13th at 4 pm Eastern Daylight Time

VolitionRx Limited Announces Full Fiscal Year 2016 Financial Results and Business Update

VolitionRx Limited to Present at the 29th Annual ROTH Conference

VolitionRx Limited Schedules Fourth Quarter and Full Year 2016 Earnings Conference Call and Business Update

A Logistics and Pathway Design Study for Volition's CE Marked NuQ(TM) Triage Test has been Commenced in the Capital Region of Denmark

VolitionRx Limited's Triage Test Results Validated in Prospective Trial

VolitionRx Limited to Attend the BTIG 2017 Medical Technology, Life Sciences, and Diagnostics Conference

VolitionRx Limited to Present at Source Capital Group's 2nd Annual Disruptive Growth & Healthcare Conference on February 15, 2017

VolitionRx Limited Strengthens Team with Key Appointment to Drive Sales and Trials in Asia

VolitionRx Limited's Novel Cancer Diagnostic Test Achieves CE Marking as it Prepares for Launch Across Europe

VolitionRx Limited to Present at 9th Annual Biotech Showcase Conference

VolitionRx Limited to Attend Citi 2016 Global Healthcare Conference

VolitionRx Limited to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2016

VolitionRx Limited Announces Third Quarter 2016 Financial Results and Business Update

VolitionRx Limited Schedules Third Quarter 2016 Earnings Conference Call and Business Update

VolitionRx Limited and Hvidovre Hospital Begin Large Prospective Clinical Study

VolitionRx Limited Announces Acquisition of New Belgian Facility and Appointment of COO to Belgian Volition

VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriter

Triage Blood Test Data Presented to Leading International Experts at the World Endoscopy Organization's Colorectal Cancer Screening Committee

Data Presented at ESMO 2016 Demonstrates that VolitionRx Limited's Novel Blood Test for Colorectal Cancer Potentially Reduces the Need for Colonoscopy Referral by 25%

VolitionRx Limited Announces Closing of Public Offering of Common Stock

VolitionRx Limited Announces Pricing of Public Offering of Common Stock

VolitionRx Limited Announces Proposed Public Offering of Common Stock

VolitionRx to Attend Several Conferences in September

Volition's Nu.Q Triage Colorectal Cancer Screening Test Expected to Reduce Colonoscopy Referral by 25 Percent

VolitionRx Schedules Product Launch Update Conference Call for Tuesday, September 6, 2016 at 8:30 am ET

VolitionRx Announces Second Quarter 2016 Financial Results and Business Update

VolitionRx Schedules Second Quarter 2016 Earnings Conference Call and Business Update for Thursday, August 11, 2016 at 8:30am ET

VolitionRx Engages Edison Advisors as Investor Relations Counsel

VolitionRx Granted Fourth U.S. Patent

VolitionRx Appoints Dr. Edward Futcher to Board of Directors

VolitionRx Publishes Study Confirming Stability of Circulating Cell-Free Nucleosomes as Biomarkers for Cancer Diagnostic Blood Tests

VolitionRx to Present at Two Upcoming Conferences in June

VolitionRx to Present Data Demonstrating Accuracy of NuQ® Blood Test in Detecting Colorectal Cancer at World Endoscopy Organization (WEO) Meeting

VolitionRx Announces First Quarter 2016 Financial Results and Business Update

VolitionRx Initiates Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ(R) Blood Test for Pancreatic Cancer

VolitionRx Schedules First Quarter 2016 Earnings Conference Call and Business Update for Friday, May 13, 2016 at 8:30am ET

VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test

VolitionRx Appoints Louise Day as Chief Marketing and Communications Officer

VolitionRx to Participate in 2016 Morgan Stanley Healthcare Insight Series

VolitionRx to Present at AACR Annual Meeting and Announce First Results from Prostate Cancer Study

VolitionRx Announces CE Marks for Two NuQ® Blood Assays for Detection of Colorectal Cancer

VolitionRx Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full

VolitionRx Announces Pricing of Public Offering of Common Stock

VolitionRx Announces Proposed Public Offering of Common Stock

VolitionRx Announces Full Year 2015 Financial Results and Business Update

VolitionRx Schedules Full-Year 2015 Earnings Conference Call and Business Update for Friday, March 11, 2016 at 8:30am ET

Preliminary Data Demonstrates 86% Accuracy in Detecting Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease

VolitionRx Demonstrates 75% Accuracy in Detecting Highest-Risk Pre-Cancerous Colorectal Adenomas with NuQ® Blood Test

VolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection

/C O R R E C T I O N -- VolitionRx Ltd/

VolitionRx Initiates Prostate Cancer Study in Collaboration with the Surrey Cancer Research Institute, University of Surrey, UK

VolitionRx Receives International ISO Certification for Quality Management System of its NuQ(R) Blood Tests

VolitionRx Releases Annual Shareholder Update Letter

VolitionRx Announces Dr. Jason Terrell's Transition to Full-Time Status as Chief Medical Officer and Head of U.S. Operations

VolitionRx Granted Its Third U.S. Patent

VolitionRx Demonstrates More Than 90% Accuracy for Colorectal Cancer NuQ(R) Blood Test in Completed Prospective Study

VolitionRx to Present at LD Micro Conference on December 3 in Los Angeles

VolitionRx Demonstrates NuQ® Blood Test Detects Lung Cancers with more than 90% Accuracy

VolitionRx Granted Its Second U.S. Patent

VolitionRx to Present at Two Conferences in November

VolitionRx Announces Third Quarter 2015 Financial Results and Business Update

VolitionRx Schedules Third Quarter 2015 Earnings Conference Call and Business Update for Wednesday, November 4, 2015 at 8:30am ET

VolitionRx Demonstrates NuQ® Blood Test Detects 95% of Pancreatic Cancers in Second Preliminary Study

VolitionRx Announces Publication of Results from Pancreatic Cancer Study with Lund University in Clinical Epigenetics

VolitionRx Announces First CE Mark for NuQ(R) Blood Assay for Detection of Colorectal Cancer

VolitionRx Granted Its First U.S. Patent

VolitionRx Demonstrates NuQ(R) Blood Test Detects 81% of Colorectal Cancers and 67% of High Risk Adenomas in Large Double Blinded Clinical Trial

VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015

VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015

VolitionRx Announces Appointment of David Kratochvil as Chief Financial Officer

VolitionRx Announces Second Quarter 2015 Financial Results and Business Update

VolitionRx Schedules Second Quarter 2015 Earnings Conference Call and Business Update for Tuesday, August 11, 2015 at 8:30am ET

VolitionRx to Present at Wedbush PacGrow Healthcare Conference

VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs

VolitionRx CSO Dr. Jake Micallef to Present Scientific Webinar

VolitionRx Expands Scientific Advisory Board

VolitionRx -- placeholder 2015

VolitionRx Partners with Two Market Access Consulting Agencies to Support Market Access of NuQ(R) Colorectal Cancer Tests in Europe

VolitionRx to Present at Two Upcoming Investor Conferences

VolitionRx CEO Cameron Reynolds to Present Informational Webinar

VolitionRx Announces First Quarter 2015 Financial Results and Business Update

VolitionRx Accelerates Clinical Trial with University Hospital Bonn, Germany Evaluating NuQ® Assays in Most Prevalent Cancers

VolitionRx Schedules First Quarter 2015 Earnings Conference Call and Business Update for Tuesday, May 12, 2015 at 8:30 a.m. ET

VolitionRx Initiates Study with Hvidovre Hospital, Denmark, Specifically to Target NuQ(R) Biomarker Panel for Colorectal Polyps

VolitionRx Adds Three New Laboratory Automation Systems to Expedite Sample Analysis for its Large Ongoing Clinical Trials

VolitionRx Initiates Second Prostate Cancer Pilot Study Assessing Nucleosomics(R) Technology

VolitionRx Acquires Direct Ownership of Nucleosomics® Technology Patent

VolitionRx Limited Announces Exercise of Over-Allotment Option in Previously Announced Public Offering

VolitionRx Limited Prices Public Offering of Common Stock

VolitionRx Begins First Ovarian Cancer Detection Study

Initial Study Demonstrates that VolitionRx NuQ® Blood Test Has 84% Accuracy in Detecting Early Stage Treatable Pancreatic Cancers

VolitionRx to Initiate Study with University Hospital Bonn to Confirm NuQ® Test Accuracy in Lung Cancer

VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014

VolitionRx Enters Agreement with University of Oxford to Initiate Endometriosis Study

VolitionRx to Present at the SeeThruEquity Conference

VolitionRx Initiates Sponsorship of Two-time Cancer Survivor to Drive Awareness for the Importance of Early Cancer Detection

VolitionRx Presents Further Colorectal Cancer Data at 9th International Conference of Anticancer Research

VolitionRx Announces Prostate Cancer Collaboration with the University of Texas MD Anderson Cancer Center

VolitionRx NuQ(R) Blood Test Detects 84% of Colorectal Cancers; Including Both Early- and Later-stage Cancers

VolitionRx to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference

VolitionRx Invests in Laboratory Automation System to Increase Throughput Capacity for Large Clinical Trials

VolitionRx Announces New Chief Financial Officer

VolitionRx -- placeholder 2014

VolitionRx Sells First NuQ® Research Use Only Kits to Active Motif

VolitionRx Appoints Dr. Habib Skaff to Board of Directors

VolitionRx Announces First Published Data in Anticancer Research Journal

VolitionRx Extends Agreement With University Hospital Bonn to Include CE Mark Performance Evaluation

President and CEO of VolitionRx Issues Corporate Update

New VolitionRx Study Data Demonstrates NuQ(R) Assays' High Detection Rate of Prostate Cancer and the Ability to Distinguish Between Prostate and Colorectal Cancer

VolitionRx Completes $3 Million Private Placement

VolitionRx Commences First Large Clinical Trial in Collaboration With Hvidovre Hospital, Denmark

VolitionRx Presents at MicroCapClub Invitational

VolitionRx Announces Engagement of MissionIR Investor Relations Services

VolitionRx Finds Simple Blood Test Detects 85% of Colorectal Cancers and Over 50% of Polyps

VolitionRx to Present at the 6th Annual LD Micro Conference

VolitionRx Expands Sample Size to 11,000 in Pivotal Colorectal Cancer Trial with Hvidovre Hospital, Denmark

First VolitionRx Study Data Presented at CNAPS, Baltimore

VolitionRx and Active Motif enter into Distribution Agreement for Volition's Research Use Only ELISA Kits

VolitionRx-led Consortium Awarded euro 780 000 ($1M approx.) Eurostars Grant

VolitionRx to use Innova Biosciences' Biotin Technology in its Epigenetic Research Kits

VolitionRx -- placeholder 2013

VolitionRx Embarks on Colorectal Cancer Trial with Hvidovre Hospital, Denmark

Racepoint Group Appointed by VolitionRx to Raise Awareness of its new Early-Stage Cancer Diagnostic

VolitionRx Files Two Patent Applications

VolitionRx Hires Head of US Operations, Jason Terrell MD

VolitionRx Announces Collaboration with Wales Cancer Bank

Volition Launches NuQ® Epigenetic Immunoassays for Research Use

VolitionRX to Begin Prospective Clinical Trial in Colon Cancer

VolitionRX Issues CEO Letter to Shareholders

VolitionRX Signs Collaboration Agreement With Stefan Holdenrieder of Rheinische Friedrich-Wilhelms-Universitat Bonn Germany

VolitionRx -- placeholder 2012

VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests

Pioneering New Science Nucleosomics Advances Blood Based Diagnostics for Cancer

Volition Signs Collaboration Agreement With Abcodia

VolitionRX Limited Intellectual Property Update: New Patent Filed

VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement

Volition Ticker Symbol Changed to VNRX.OB; Name Change to VolitionRX Limited Completed

VolitionRx -- placeholder 2011